Prioritisation workshop: how can we
meet the Strategy to 2020 target and
what does it mean for individual review
groups?
DAVID TOVEY, RUTH FOXLEE AND SERA TORT
Workshop aims:
◦
◦
◦
◦
Describe target and approach taken so far
Share responses from internal groups
Share published information from external organisations
Discussion on how groups can use the various sources and
data
◦ Discussion on what this means for the Strategy 2020
target.
Workshop plan
Welcome and introductions
Presentation
◦ What does the target say?
◦ What are we planning?
◦ What have we done?
Discussion
◦ How can we build on what has been done?
◦ What can we learn?
◦ How can we maximise the usefulness of the work?
◦ Next steps?
Target 1.1: General description
Develop a list of approximately 200 new high-priority and ‘to-update’ Cochrane
Systematic Reviews that will direct production priorities; and establish a
decision-making framework that will enable the priority list to be updated at
regular intervals.
Target 1.1: Indicators of success:
Cochrane groups and the Central Executive team have engaged with a cross-section of
users (including patients and other healthcare consumers, health practitioners, policymakers, guidelines developers and existing and potential research funders) to identify
questions that are most relevant and important to them.
A list of approximately 200 new high-priority and ‘to-update’ Cochrane Systematic
Reviews that will direct organisation-wide production priorities for 2015 onwards has
been developed.
100 new reviews from the list have been commissioned (review author teams identified
and titles registered).
A priority-setting decision-making framework for Cochrane Systematic Reviews is in
place.
Target 1.1: Timing
◦ List and decision-making framework completed by end of
December 2014.
◦ Commissioning of 100 new reviews from the list completed by July
2015.
Initial plan
Internal work
◦ Support from CRGs and Fields
◦ Updating decisions
◦ Data gathering: access / citations
◦ Tools
External work
◦ Prioritisation and Agenda Setting Methods Group project
◦ Data gathering: published research priorities
◦ Meetings with selected external organisations
◦ Burden of disease work
Internal groups
Initial request from CRGs and Fields for recent or current work on priority
setting:
◦ The evidence for it being a priority
◦ At least one user group for which this is a priority
◦ The source of the priority e.g. funder, data analysis etc. and, if appropriate,
the process involved
◦ The research question/review title(s) you have identified.
Updating
Access and citation data
◦ Email CRGs: highest 20 cited
◦ Individual CRG reports
Decision tools
◦ 3 tools
Tool 1: prioritisation criteria
Tools 2 & 3: Qualitative and quantitative
decision tools
Step 1: Is the clinical question answered or no longer relevant?
Step 2: Are there any new factors to consider?
Steps 3 & 4: Are there new studies?
Are the conclusions likely to change?
Tool 3: Statistical prediction tool
About metarank
Based on minimal information on the new evidence
◦ assumes an update strategy is in place such that number of new studies and
their sample sizes are known
‘Signals’ of the need to update implemented as a STATA user-written function
Performs simulation of several meta-analyses, each with one or more new studies
of different sizes
Decision tool: summary
The decision tool provides a set of criteria that can be used to assess
whether to update a Cochrane Review.
The tool can be applied to a single Cochrane Review or can be used
to prioritise a suite of reviews (e.g. those from an individual
Cochrane Review Group)
External sources of data
Sources – countries & organisations
Australia
◦ AusAID, National Health and Medical Research Council (NHMRC) & Pharmaceutical Benefits Scheme (PBS)
Canada
◦ Canadian Institutes of Health Research (CIHR)
Saudi Arabia
◦ Ministry of Health
UK
◦ Evidence Aid, James Lind Alliance, Medical Research Council (MRC), NICE Guidelines, NICE Research
Recommendations Database, Scottish Intercollegiate Guideline Network (SIGN), Welcome Trust
USA
◦ Agency for Health Research Quality (AHRQ), Patient-Centered Outcomes Research (PCORI), USAID
International
◦ WHO Essential Medicine List, World Heart Federation
Sources – Spain
Instituto de Salud Carlos III (ISCII)
CIBER-BBN. Biomedical Research Networking
Centre In Bioengineering, Biomaterials &
Nanomedicine
CIBERDEM. Network Biomedical Research
Centre in Diabetes and Associated Metabolic
Disorders
CIBEREHD. Network Biomedical Research
Centre in Hepatic & Digestive Diseases
CIBERER. Network Biomedical Research Centre
in Rare Diseases
CIBERES. Network Biomedical Research Centre
in Respiratory Diseases
CIBERESP. Network Biomedical Research
Centre in Epidemiology & Public Health
CIBEROBN. Network Biomedical Research
Centre Obesity & Nutrition
CIBERSAM. Network Biomedical Research
Centre in Mental Health
Centro Superior de Investigaciones Científicas.
The Spanish National Research Council (CSIC)
GuiaSalud (Guidelines)
Health Technology Agencies
Top 10 priority areas by CRG
Public Health
Heart
Effective Practice & Organisation of Care
Pregnancy & Childbirth
Musculoskeletal
Airways
Developmental, Psychosocial & Learning
Problems
Depression, Anxiety & Neurosis
Metabolic & Endocrine Disorders
Drugs & Alcohol
Top research priorities by browse topic
Public Health
Heart & circulation
Cancer
Mental health
Lung & airways
Neurology
Pregnancy & Childbirth
Effective practice/health systems
Infectious Disease
Developmental, Psychosocial & Learning Problems
Endocrine & metabolic
Orthopaedics & trauma
Tobacco, Drugs & Alcohol
Country
Organisation
Specific topic area
CEU/CLib topic CRG
area
Australia
NHMRC
Asthma
Lung & airways
Airways
Australia
Pharmaceutical Is there any new evidence on the efficacy and safety of single ingredient inhaled corticosteroid vs. fixed dose combination (FDC) inhaled long-acting
Benefits
beta-agonists and inhaled corticosteroids?
Scheme (PBS)
Lung & airways
Airways
Canada
Canadian
Growing prevalence and burden of chronic diseases, including mental illness and neurodegenerative diseases, in an aging population: heart disease,
Institutes
cancer, diabetes, obesity, asthma, allergy and arthritis, as well as mental illness, addiction and substance abuse
of Health
Research (CIHR)
Lung & airways
Airways
Spain
CIBERES
CIBERES has implemented the following 9 CRPs that include 32 research lines and 97 active research projects: Asthma, Sleep Apnea, Lung Cancer,
COPD, Pulmonary Fibrosis, Acute Lung Injury, Pneumonia, Pathogen - Host interactions, Tuberculosis
Lung & airways
Airways
Spain
GuiaSalud
(Guidelines)
In development: Asthma update
Lung & airways
Airways
UK
James Lind
Alliance
Asthma priority setting partnership top 10:
Lung & airways
1a. What are the adverse effects associated with long term use of short and long actingbronchodilators; inhaled and oral steroids; and combination and
additive therapies in adults? (N.B this includes children aged 12 years old and over) 1b. What are the adverse effects associated with long term use of
short and long acting bronchodilators; inhaled and oral steroids; and combination and additive therapies in children? 2. What is the most effective way
of managing asthma with other health problems? 3. What are the key components of successful "Self Management" for a person with asthma? 4. What
is the most effective strategy to educate people with asthma and health professionals about managing the adverse effects of drug therapies? 5. What
is the most effective way of managing asthma triggers? 6. What is the role of complementary therapies in asthma management? 7. What are the
benefits of breathing exercises as a form of physical therapy for asthma? 8. What type of patient (children and adults) and health professional
education is most effective in gaining asthma control? 9. What is the most effective way to manage consultations and asthma control in adolescence
and young people? 10. Psychological interventions for adults with asthma?
Airways
UK
NICE
(Guidelines)
Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (CG101)
Lung & airways
Airways
UK
NICE (Research Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and Nobreath (DG12): 1) NICE also considered the role of
Lung & airways
recommendatio FeNO measurement in asthma management. It accepted that currently available evidence on the use of FeNO measurement in asthma management is
ns)
unclear on whether benefits of treatment are maintained long-term. NICE concluded that long-term studies following patients for several years could
address this gap. 2) NICE also considered the role of FeNO in guiding inhaled corticosteroid dosing through stepping-up and stepping-down protocols.
It accepted there is a need for more evidence on which protocols offer the safest and most optimal asthma management when used in UK clinical
practice. Therefore, further studies are recommended, with consideration for the different protocols and cut-off points that may be necessary in
different populations. 3) NICE discussed the potential for future research. NICE accepted that there is a need to further establish the accuracy of
current practice in diagnosing asthma and the incremental accuracy associated with the addition of FeNO testing.
Airways
UK
Scottish
Asthma: The guideline is being updated to incorporate new evidence for recommendations on pharmacological, non-pharmacological and self
Intercollegiate management. (Update in progress, due Summer 2014)
Guideline
Network (SIGN)
Airways
Lung & airways
Country
Organisation
Specific topic area
CEU/CLib topic CRG
area
Australia
NHMRC
Asthma
Lung & airways
Airways
Australia
Pharmaceutical Is there any new evidence on the efficacy and safety of single ingredient inhaled corticosteroid vs. fixed dose combination (FDC) inhaled long-acting
Benefits
beta-agonists and inhaled corticosteroids?
Scheme (PBS)
Lung & airways
Airways
Canada
Canadian
Growing prevalence and burden of chronic diseases, including mental illness and neurodegenerative diseases, in an aging population: heart disease,
Institutes
cancer, diabetes, obesity, asthma, allergy and arthritis, as well as mental illness, addiction and substance abuse
of Health
Research (CIHR)
Lung & airways
Airways
Spain
CIBERES
CIBERES has implemented the following 9 CRPs that include 32 research lines and 97 active research projects: Asthma, Sleep Apnea, Lung Cancer,
COPD, Pulmonary Fibrosis, Acute Lung Injury, Pneumonia, Pathogen - Host interactions, Tuberculosis
Lung & airways
Airways
Spain
GuiaSalud
(Guidelines)
In development: Asthma update
Lung & airways
Airways
UK
James Lind
Alliance
Asthma priority setting partnership top 10:
Lung & airways
1a. What are the adverse effects associated with long term use of short and long actingbronchodilators; inhaled and oral steroids; and combination and
additive therapies in adults? (N.B this includes children aged 12 years old and over) 1b. What are the adverse effects associated with long term use of
short and long acting bronchodilators; inhaled and oral steroids; and combination and additive therapies in children? 2. What is the most effective way
of managing asthma with other health problems? 3. What are the key components of successful "Self Management" for a person with asthma? 4. What
is the most effective strategy to educate people with asthma and health professionals about managing the adverse effects of drug therapies? 5. What
is the most effective way of managing asthma triggers? 6. What is the role of complementary therapies in asthma management? 7. What are the
benefits of breathing exercises as a form of physical therapy for asthma? 8. What type of patient (children and adults) and health professional
education is most effective in gaining asthma control? 9. What is the most effective way to manage consultations and asthma control in adolescence
and young people? 10. Psychological interventions for adults with asthma?
Airways
UK
NICE
(Guidelines)
Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (CG101)
Lung & airways
Airways
UK
NICE (Research Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and Nobreath (DG12): 1) NICE also considered the role of
Lung & airways
recommendatio FeNO measurement in asthma management. It accepted that currently available evidence on the use of FeNO measurement in asthma management is
ns)
unclear on whether benefits of treatment are maintained long-term. NICE concluded that long-term studies following patients for several years could
address this gap. 2) NICE also considered the role of FeNO in guiding inhaled corticosteroid dosing through stepping-up and stepping-down protocols.
It accepted there is a need for more evidence on which protocols offer the safest and most optimal asthma management when used in UK clinical
practice. Therefore, further studies are recommended, with consideration for the different protocols and cut-off points that may be necessary in
different populations. 3) NICE discussed the potential for future research. NICE accepted that there is a need to further establish the accuracy of
current practice in diagnosing asthma and the incremental accuracy associated with the addition of FeNO testing.
Airways
UK
Scottish
Asthma: The guideline is being updated to incorporate new evidence for recommendations on pharmacological, non-pharmacological and self
Intercollegiate management. (Update in progress, due Summer 2014)
Guideline
Network (SIGN)
Airways
Lung & airways
Country
Organisation
Specific topic area
CEU/CLib topic CRG
area
Australia
NHMRC
Asthma
Lung & airways
Airways
Australia
Pharmaceutical Is there any new evidence on the efficacy and safety of single ingredient inhaled corticosteroid vs. fixed dose combination (FDC) inhaled long-acting
Benefits
beta-agonists and inhaled corticosteroids?
Scheme (PBS)
Lung & airways
Airways
Canada
Canadian
Growing prevalence and burden of chronic diseases, including mental illness and neurodegenerative diseases, in an aging population: heart disease,
Institutes
cancer, diabetes, obesity, asthma, allergy and arthritis, as well as mental illness, addiction and substance abuse
of Health
Research (CIHR)
Lung & airways
Airways
Spain
CIBERES
CIBERES has implemented the following 9 CRPs that include 32 research lines and 97 active research projects: Asthma, Sleep Apnea, Lung Cancer,
COPD, Pulmonary Fibrosis, Acute Lung Injury, Pneumonia, Pathogen - Host interactions, Tuberculosis
Lung & airways
Airways
Spain
GuiaSalud
(Guidelines)
In development: Asthma update
Lung & airways
Airways
UK
James Lind
Alliance
Asthma priority setting partnership top 10:
Lung & airways
1a. What are the adverse effects associated with long term use of short and long actingbronchodilators; inhaled and oral steroids; and combination and
additive therapies in adults? (N.B this includes children aged 12 years old and over) 1b. What are the adverse effects associated with long term use of
short and long acting bronchodilators; inhaled and oral steroids; and combination and additive therapies in children? 2. What is the most effective way
of managing asthma with other health problems? 3. What are the key components of successful "Self Management" for a person with asthma? 4. What
is the most effective strategy to educate people with asthma and health professionals about managing the adverse effects of drug therapies? 5. What
is the most effective way of managing asthma triggers? 6. What is the role of complementary therapies in asthma management? 7. What are the
benefits of breathing exercises as a form of physical therapy for asthma? 8. What type of patient (children and adults) and health professional
education is most effective in gaining asthma control? 9. What is the most effective way to manage consultations and asthma control in adolescence
and young people? 10. Psychological interventions for adults with asthma?
Airways
UK
NICE
(Guidelines)
Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (CG101)
Lung & airways
Airways
UK
NICE (Research Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and Nobreath (DG12): 1) NICE also considered the role of
Lung & airways
recommendatio FeNO measurement in asthma management. It accepted that currently available evidence on the use of FeNO measurement in asthma management is
ns)
unclear on whether benefits of treatment are maintained long-term. NICE concluded that long-term studies following patients for several years could
address this gap. 2) NICE also considered the role of FeNO in guiding inhaled corticosteroid dosing through stepping-up and stepping-down protocols.
It accepted there is a need for more evidence on which protocols offer the safest and most optimal asthma management when used in UK clinical
practice. Therefore, further studies are recommended, with consideration for the different protocols and cut-off points that may be necessary in
different populations. 3) NICE discussed the potential for future research. NICE accepted that there is a need to further establish the accuracy of
current practice in diagnosing asthma and the incremental accuracy associated with the addition of FeNO testing.
Airways
UK
Scottish
Asthma: The guideline is being updated to incorporate new evidence for recommendations on pharmacological, non-pharmacological and self
Intercollegiate management. (Update in progress, due Summer 2014)
Guideline
Network (SIGN)
Airways
Lung & airways
Country
Organisation
Specific topic area
Canada
Canadian
Prepare for and respond to existing and emerging global threats to health: acute respiratoty infections (influenza,
Institutes
SARS), HIV/AIDS
of Health
Research (CIHR)
CIBERES
CIBERES has implemented the following 9 CRPs that include 32 research lines and 97 active research projects:
Asthma, Sleep Apnea, Lung Cancer, COPD, Pulmonary Fibrosis, Acute Lung Injury, Pneumonia, Pathogen - Host
interactions, Tuberculosis
CEU/CLib
topic area
CRG
Lung &
airways
Acute
Respiratory
Infections
Lung &
airways
Acute
Respiratory
Infections
UK
Medical
Antimicrobial resistance: The growing resistance of micro-organisms to antimicrobial therapies such as antibiotics is Lung &
Research Council a significant global Public Health issue. Too few new treatments are in development, and we need more diagnostics airways
(MRC)
that will help us to match treatments with infections. The UK’s Chief Medical Officer has raised the alarm around
antibiotic resistance (AMR), and the Department of Health has released a Five Year Antimicrobial Resistance
strategy (2013-2018). The World Economic Forum has suggested that AMR be added to the global risk register, and
the WHO has highlighted the serious implications for global Public Health in its AMR Global Report on Surveillance.
Only a multidisciplinary approach will succeed in tackling the rise in AMR. The research councils, along with other
UK funders, have been working together to identify a number of research opportunities and challenges to tackling
the rise in AMR within four themes - 1: Understanding resistant bacteria in context of the host. 2: Accelerating
therapeutic and diagnostics development. 3: Understanding the real world interactions. 4: Behaviour within and
beyond the health care setting.
Acute
Respiratory
Infections
UK
NICE
(Guidelines)
Bacterial meningitis & meningococcal septicaemia (CG102)
USA
USAID
USAID with its partners in the U.S. Government and the global community are committed to the goal of ending
Lung &
preventable child and maternal deaths. While many challenges remain, today, more than ever, we are equipped
airways
with the tools and knowledge to reach this goal. The health of mothers and children around the world is linked to
improvements in maternal health, which inherently affect child health. Over the past two decades, there has been
a nearly 50 percent reduction in maternal deaths, from 543,000 in 1990 to 287,000 in 2010. Meanwhile, the annual
number of under-five deaths declined from 12.6 million in 1990 to 6.6 million in 2012. While under-five mortality is
declining faster now than in the past two decades, with the annual rate of reduction more than tripling in 2005-2012
compared to the rate in 1990-1995, 18,000 children still die every day. The U.S. cannot act alone and in order to meet
the Millennium Development Goal Four (Reduce Child Mortality) target by its agreed date of 2015, an additional 3.5
million children's lives above the current trend rate will need to be saved between 2013 and 2015.
Acute
Respiratory
Infections
Acute
Spain
Lung &
airways
Respiratory
Infections
Country
Organisation
Specific topic area
Canada
Canadian
Support a high-quality, accessible and sustainable health-care system: drug safety, optimising the use of Electronic Health Records (EHRs), safety in Consumer &
Institutes
long-term care facilities, recruitment and retention of physicians in rural regions and priority setting for new and expensive cancer drugs
Communication
of Health Research
Strategies
(CIHR)
Consumer &
Communication
Strategies
UK
NICE (Guidelines)
Consumer &
Communication
Strategies
Consumer &
Communication
Strategies
UK
NICE (Research
Behaviour change: individual approaches (PH49): 1) How effective and cost effective are behaviour change interventions delivered remotely (that Consumer &
recommendations) is, by telephone, text message, phone and tablet apps or the internet)? How does this vary among behaviours and among people from different
Communication
sociodemographic groups? 2) Which combinations of behaviour change techniques and modes of delivery are effective and cost effective in
Strategies
initiating particular behaviour changes, and in maintaining those changes? How does this vary among people from different socio-demographic
groups or with different levels of motivation, access to information or skills? Include research that builds the evidence base on the effectiveness of
each behaviour change technique. For example, experimental and meta-analytic work could clarify which behaviour change techniques work when,
and for whom? 3) How do behaviour change techniques lead to change? What are the best methods of testing the relationship between the
theories that describe change processes and the effectiveness of interventions in practice? 4) Which behaviour change interventions and
programmes are effective and cost effective at changing multiple behaviours and maintaining behaviour change? How does this vary among people
from different sociodemographic groups? 5) Which choice architecture interventions help to reduce increased-risk and higher-risk drinking of
alcohol, improve sexual health behaviours, help stop or reduce smoking, or increase the physical activity levels of the general UK population? How
is this related to sociodemographic variables? 6) What evidence of effectiveness is there on the use of choice architecture interventions in
commercial settings to influence health-related behaviours? How can findings from commercial settings support non-commercial choice
architecture approaches to support behaviour change to improve health? 7) What characteristics of behaviour change training influence the
effectiveness of behaviour change practitioners?
Consumer &
Communication
Strategies
USA
Agency for Health
Research Quality
(AHRQ) Research
Funding Priorities
AHRQ is interested in funding focused research demonstration projects that provide evidence to inform the safe use of health IT. (1) Clinical patient Consumer &
safety: Clinical patient safety topics impacted most by health IT. (2) EHR system integrity: Frequency of and optimal mitigation strategies for EHR
Communication
downtimes. (3) Health IT safety reporting: Optimal health IT patient safety reporting strategies (4) Design, implementation, usability, and safe use Strategies
of health IT by all users, including patients.
Consumer &
Communication
Strategies
USA
Patient-Centered
Outcomes
Research (PCORI)
Consumer &
communication
strategies
Consumer &
Communication
Strategies
USA
Patient-Centered
Outcomes
Research (PCORI)
Communication and dissemination research: (1) Research that compares alternative communication, dissemination, health literacy, and
implementation strategies that aim to improve shared decision-making by empowering people to be more engaged, increasing clinician and
patient awareness of healthcare options, and use of comparative effectiveness research results at the point of decision-making. (2) Research that
compares the effectiveness, across a range of patient-centered outcomes, of alternative approaches to increase or encourage effective patient
participation in care decisions and in shared decision-making. (3) Studies to develop and compare alternative methods and tools to include patientdesired outcomes in the healthcare decision-making process. (4) Research that compares innovative approaches in the use of existing electronic
clinical data and other electronic modalities from the healthcare system or from a network of systems to enhance clinical decision-making by
patients and providers.
Addressing disparities: (1) Research that compares interventions to reduce or eliminate disparities in health outcomes, for example, by accounting
for possible differences in patient preferences or differences in response to therapy across socioeconomic, demographic, and other patient
characteristics. (2) Research that compares benefits and risks of treatment, diagnostic, prevention, or service options across different patient
populations, with attention to eliminating 18 disparities that are not a result of patient preference. (3) Research that compares strategies to
overcome barriers (e.g., language, culture, transportation, homelessness, unemployment, lack of family/caregiver support that may adversely
affect patients and is relevant to their choices for preventive, diagnostic, and treatment strategies or their outcomes. (4) Research that compares
and identifies best practices within various patient populations for information sharing about treatment outcomes and patient-centered research.
Consumer &
Communication
Strategies
Consumer &
Communication
Strategies
Medicines adherence (CG76)
CEU/CLib topic CRG
area
Country
Organisation
Broad topic Specific topic area
area
CRG
Australia
NHMRC
Dementia
Dementia
Dementia & Cognitive
Improvement
Australia
Pharmaceutical
Benefits Scheme
(PBS)
Dementia
Is there more recent evidence on the safety and efficacy of cholinesterase inhibitor (CEI) medicines to treat Alzheimer disease that would
inform the PBAC about their cost-effectiveness?
Dementia & Cognitive
Improvement
UK
James Lind Alliance
Dementia
Dementia top 10 priorities: 1. What are the most effective components of care that keep a person with dementia as independent as they Dementia & Cognitive
can be at all stages of the disease in all care settings? 2. How can the best ways to care for people with dementia, including results from
Improvement
research findings, be effectively disseminated and implemented into care practice? 3. What is the impact of an early diagnosis of dementia
and how can primary care support a more effective route to diagnosis? 4. What non-pharmacological and/or pharmacological (drug)
interventions are most effective for managing challenging behaviour in people with dementia? 5. What is the best way to care for people
with dementia in a hospital setting when they have acute health care needs? 6. What are the most effective ways to encourage people with
dementia to eat, drink and maintain nutritional intake? 7. What are the most effective ways of supporting carers of people with dementia
living at home? 8. What is the best way to care for people with advanced dementia (with or without other illnesses) at the end of life? 9.
When is the optimal time to move a person with dementia into a care home setting and how can the standard of care be improved? 10.
What are the most effective design features for producing dementia friendly environments at both the housing and neighbourhood levels?
UK
NICE (Guidelines)
Neurology
Diagnosis, prevention and management of delirium (CG103)
UK
NICE (Guidelines)
Neurology
Dementia: Supporting people with dementia and their carers in health and social care (CG42)
Dementia & Cognitive
Improvement
Dementia & Cognitive
Improvement
How useful are these data?
Are there any other organisations or data that would be useful?
Do you already engage with any of these organisations to help set review
production priorities?
Are some of the topics more useful than others, e.g. should we concentrate on
priorities in guideline development?
Would it be useful to receive a list of priority topics area for your group and how
might you use them?
What are the comparative merits of grouping priority topics by CRG vs. browse
topic category?
Workshop plan
Welcome and introductions
Presentation
◦ What does the target say?
◦ What are we planning?
◦ What have we done?
Discussion
◦ How can we build on what has been done?
◦ What can we learn?
◦ How can we maximise the usefulness of the work?
◦ Next steps?